Smaller US winter COVID wave adds pressure to Pfizer turnaround
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could put additional pressure on Pfizer to find growth from its non-COVID treatments. Pfizer, which reports financial results on Tuesday, has been under pressure from investors looking for an improved performance from its other products, such as its cancer drugs, to make up for COVID sales, which have crashed from their pandemic peak of close to $60 billion in revenue. COVID products are still a profit driver for the company.